The Damon Runyon Cancer Research Foundation has named four outstanding young scientists as recipients of the prestigious Damon Runyon-Sohn Pediatric Cancer Research Fellowship Award, committing nearly $1 million to help address a critical shortage of funding for pediatric cancer research.
Media Room--We can provide journalists with expert commentary on topics like:
- Challenges facing early career scientists, and new technologies and trends in cancer research (all forms of cancer)
- Connections to bright, articulate early career scientists involved in leading-edge cancer research projects
- Introductions to scientists and doctors nationwide, and interviews with our President and CEO, Chief Scientific Officer, or others
Contact: Peter Cleary, Director of Communications 212-455-0504 or 347-322-9695, email firstname.lastname@example.org
Press releases listed below, and visit New Discoveries for breakthroughs from our scientists.
Mission: To accelerate breakthroughs, the Damon Runyon Cancer Research Foundation provides today’s best young scientists with funding to pursue innovative cancer research. The Foundation supports emerging leaders who have great potential to achieve breakthroughs in how we diagnose, treat and prevent cancer. Since its founding in 1946, the Foundation has invested over $300 million and funded more than 3,500 young scientists. 100% of all donations to the Foundation are used to support scientific research.
The Damon Runyon Cancer Research Foundation named seven new Damon Runyon Clinical Investigators at its spring 2016 Clinical Investigator Award Committee review. The recipients of this prestigious three-year award are outstanding early career physician-scientists conducting patient-oriented cancer research at major research centers under the mentorship of the nation’s leading scientists and clinicians. The Foundation also awarded Continuation Grants to three Damon Runyon Clinical Investigators. This grant is designed to support Clinical Investigators who are approaching the end of their original awards and need extra time and funding to complete a promising avenue of research or initiate/continue a clinical trial.
The Damon Runyon Board of Directors approved a fellowship stipend increase as of July 1, 2016. We are pleased to offer this increase in recognition of the financial challenges faced by postdoctoral fellows, especially those living in high-cost geographic regions and with growing families.
To help increase the number of physician-scientists, the Damon Runyon Cancer Research Foundation has created the new Damon Runyon Physician-Scientist Training Award, which provides physicians who have earned an MD degree and completed clinical specialty fellowship training the opportunity to gain the research experience they need to become leaders in translational and clinical research. Damon Runyon announced that five scientists with novel approaches to fighting cancer have been named the 2016 recipients of the award.
The Damon Runyon Cancer Research Foundation yesterday honored Tom Daniel, MD, Chairman, Celgene Research and Bob Hugin, Executive Chairman, Celgene Corporation, at its 2016 Annual Breakfast at Cipriani 42nd Street® in New York City. The Breakfast raised nearly $1.4 million to support the nation’s best and brightest cancer researchers, enabling the talent capable of revolutionizing the prevention, detection, and treatment of all forms of cancer.
The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, has elected William G. Kaelin, Jr., MD and William Raveis, Jr., to its prestigious Board of Directors.
Today, the Damon Runyon Cancer Research Foundation held the fifth annual Accelerating Cancer Cures Research Symposium. The yearly meeting is designed to encourage collaboration between cancer researchers in industry and their counterparts in academia in order to overcome many of the issues that currently impede progress against cancer. Hosted by Celgene, the meeting included academic researchers from top universities and research institutions as well as scientists from Celgene, Eli Lilly and Company, Genentech, Merck, Pfizer, and Takeda Pharmaceuticals International Co.
The Damon Runyon Cancer Research Foundation is deeply saddened by the passing of Dale F. Frey, past Chairman of its Board of Directors, one of its greatest champions and dear friend. Through his vision, passion and relentless dedication to cancer research, he had a lasting impact on human life. Under Dale’s leadership for over 16 years, the Foundation grew exponentially and funded top young scientists in cancer research whose discoveries have dramatically advanced progress against cancer. He led the Foundation with the same wisdom and entrepreneurial spirit he used as the first Chairman of General Electric Asset Management. In 2010, the Dale F. Frey Award for Breakthrough Scientists was established in his honor to support the most outstanding young cancer researchers in the nation. Our hearts go out to his wife, Betty Ann, and his children and grandchildren.
The Damon Runyon Cancer Research Foundation named 19 new Damon Runyon Fellows at its fall Fellowship Award Committee review. The recipients of this prestigious, four-year award are outstanding postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators across the country. The Committee also named four new recipients of the Damon Runyon-Dale F. Frey Award for Breakthrough Scientists. This award provides additional funding to scientists completing a prestigious Damon Runyon Fellowship Award who have greatly exceeded the Foundation’s highest expectations and are most likely to make paradigm-shifting breakthroughs that transform the way we prevent, diagnose and treat cancer.
The Damon Runyon Cancer Research Foundation announced that seven scientists with novel approaches to fighting cancer have been named 2016 recipients of the Damon Runyon-Rachleff Innovation Award. The grant of $300,000 over two years is awarded each year to early career scientists whose projects have the potential to significantly impact the prevention, diagnosis and treatment of cancer. Each awardee will have the opportunity for up to two additional years of funding (up to four years total for $600,000).